Overview

Efficacy and Safety Study of Budesonide Novolizer Dry Powder Inhaler 200μg to Treat Chinese Patients With Mild to Moderate Asthma

Status:
Unknown status

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

This is an open-label, randomized, parallel Group, multicenter study to evaluate the efficacy and safety of budesonide novolizer dry powder inhaler compared with budesonide turbuhaler dry powder inhaler in Chinese mild to moderate asthma patients.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

NovaMed Pharmaceuticals Inc.

Treatments:

Budesonide